Navigation Links
Brookdale Announces Third Quarter 2007 Results
Date:11/7/2007

-term operating leases on our liquidity, the risk of loss of property pursuant to our mortgage debt and long-term lease obligations, our ability to effectively manage our growth, our ability to integrate acquisitions (including the ARC acquisition), our ability to maintain consistent quality control, unforeseen costs associated with the acquisition of new facilities, competition for the acquisition of assets, our ability to obtain additional capital on terms acceptable to us, events which adversely affect the ability of seniors to afford our monthly resident fees or entrance fees, changes in governmental reimbursement programs, our vulnerability to economic downturns, the conditions of housing markets in certain geographic areas, acts of nature in certain geographic areas, terminations of our resident agreements and vacancies in the living spaces we lease, increased competition for skilled personnel, departure of our key officers, increases in market interest rates, environmental contamination at any of our facilities, failure to comply with existing environmental laws, an adverse determination or resolution of complaints filed against us, the cost and difficulty of complying with increasing and evolving regulation, delays in obtaining regulatory approvals, and the other risks detailed from time to time in our SEC reports, including our Annual Report on Form 10-K filed with the SEC on March 16, 2007. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements in such SEC filings. Readers are cautioned not to place undue reliance on any of these forward- looking statements, which reflect our management's views as of the date of this press release and/or the associated earnings conference call. The factors discussed above and the other factors noted in our SEC filings from time to time could cause our actual results to differ significantly from those contained in any forward-looking statement. Although we belie
'/>"/>
SOURCE Brookdale Senior Living Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Brookdale Announces Third Quarter Common Stock Dividend of $0.50
2. Brookdale Announces Third Quarter 2007 Release and Earnings Call
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 2Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 3Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 4BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4ACTEMRA 28R 29 28tocilizumab 29 Studies to be Featured at the European League Against Rheumatism 28EULAR 29 Congress 47894 1ACTEMRA 28R 29 28tocilizumab 29 Studies to be Featured at the European League Against Rheumatism 28EULAR 29 Congress 47894 2ACTEMRA 28R 29 28tocilizumab 29 Studies to be Featured at the European League Against Rheumatism 28EULAR 29 Congress 47894 3ACTEMRA 28R 29 28tocilizumab 29 Studies to be Featured at the European League Against Rheumatism 28EULAR 29 Congress 47894 4SignatureForum Reveals Top Rated Aesthetic Medical Practices in U S 47889 1SignatureForum Reveals Top Rated Aesthetic Medical Practices in U S 47889 2SignatureForum Reveals Top Rated Aesthetic Medical Practices in U S 47889 3Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 1Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 2Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 3Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 4Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD 28TM 29 an Investigational Treatment for Mixed Dyslipidemia 47887 5